Development and application of fluorine doped bismuth vanadate reduced graphene oxide Nafion composite electrode as an electrochemical sensor for 4-chlorophenol.

This study describes the synthesis of fluorine-doped bismuth vanadate (F0.1BiVO4) and its composite with graphene oxide (GO) to improve charge transport properties. Based on the structural and morphological analysis such as X-Ray diffraction (XRD), Fourier Transform Infrared Spectroscopy (FT-IR), Scanning Electron Microscopy (SEM), and RAMAN the composite of F0.1BiVO4/r-GO/Nafion was successfully prepared with no filth. It was used to selectively detect the environmental contaminant 4-chlorophenol (4-CP) on a modified glassy carbon electrode (GCE). The electron channeling ability of reduced graphene oxide (r-GO) with F0.1BiVO4 yielded a great electrochemical response (ER) in cyclic voltammetry compared to pure GCE and other modified electrodes. The differential pulse voltammetry response of 4-CP was highly sensitive with the detection of limit (LOD) of 0.56 nM and a wide linear response of 0.77-45.0 nM. Fluorine doping, in particular, was able to affect the crystal growth of BiVO4, which was the primary cause of the aforementioned improvement. On the other hand, r-GO acts as an electron bridge to improve charge transfer between electrolytes and F-BiVO4 due to its high electron transport rate. These results demonstrate the effectiveness of F0.1BiVO4/r-GO/Nafion/GCE for the electrochemical detection of 4-CP.

Imidazolium-based ionic liquid functionalized mesoporous silica nanoparticles as a promising nano-carrier: response surface strategy to investigate and optimize loading and release process for Lapatinib delivery.

Imidazolium-based ionic liquid functionalized PEGylated mesoporous silica nanoparticles MCM-41 (denoted as [ImIL-PEGylated@MCM-41] NPs) is synthesized and evaluated as an efficient and reliable pH-sensitive nano-carrier for controlled release of cationic Lapatinib (Lap) drug. This nano-DDS was fully characterized by dynamic light scattering, scanning electron microscopy, X-ray powder diffraction, Fourier transform infrared spectroscopy, N2 adsorption-desorption measurement, and differential scanning calorimeter. Furthermore, the drug loading content and in-vitro drug release profile were studied. The entrapment and loading efficiency of the optimized formulation for Lap were 91 ± 2.0% and 32.21 ± 2.70%, respectively. The results of cytotoxicity assay demonstrated that ImIL-PEG@MCM-41 has no significant toxicity on both cancerous and normal cell lines and the anticancer activity of Lap@ImIL-PEG@MCM-41 was comparable to free drug in case of human breast cells (SKBR3) and human embryonic kidney 293 cells (HEK-293). Meanwhile, three-dimensional (3D) cell culture was performed by multicellular tumor spheroids for understanding of cell response to drugs in physiologically 3D microenvironments. The results of Lap@ImIL-PEG@MCM-41 uptake during 48 hours showed a gradual release of the Lap through the multicellular tumor spheroids. This showed that the pH-responsive controlled release of Lapatinib leads to the satisfactory results in the in vitro breast cancer therapy.